Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 9/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065345 | 0.89 | NOS3 (0.51) | NOS3NOS1NOS2TSHRPDK1 | |
| SCHEMBL3057449 | 0.85 | GAA (0.53) | NOS3NOS1NOS2TSHRPDK1 | |
| SCHEMBL3050032 | 0.83 | NOS3 (0.55) | NOS3NOS1NOS2TSHRPDK1 | |
| SCHEMBL3053783 | 0.83 | GAA (0.51) | NOS3NOS1NOS2TSHRPDK1 | |
| SCHEMBL3060075 | 0.83 | GAA (0.53) | NOS3NOS1NOS2TSHRPDK1 | |
| SCHEMBL3052473 | 0.82 | NOS3 (0.61) | NOS3NOS1NOS2TSHRPDK1 | |
| SCHEMBL3048615 | 0.82 | NOS3 (0.48) | NOS3NOS1NOS2TSHRPDK1 | |
| SCHEMBL3050876 | 0.81 | PDK1 (0.46) | NOS3NOS1NOS2CYP3A4TSHR | |
| SCHEMBL3065409 | 0.81 | GAA (0.63) | TSHRPDK1GAAHTT | |
| SCHEMBL3061956 | 0.80 | NOS3 (0.50) | NOS3NOS1NOS2PDK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | NOS3 3019/4885NOS1 3682/4885NOS2 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.